Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 comparison of T2769 versus Vismed Multi for moderate to severe dry eye syndrome
MOH_2023-12-05_013082Phase 3Not yet recruiting
- Sponsor
- Laboratoires Théa
- Start
- Oct 2023
- Modality
- Small Molecules, Peptides, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised trial in dry eye syndrome (DED) comparing T2769 with Vismed Multi (2 arms). Planned start Oct 2023; status: not yet recruiting.
02
Drugs
hyaluronic acid + trehalose + NAAGAhyaluronic acid sodium salt
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on MOH_2023-12-05_013082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-12-05_013082.